David Jorden
Chief Executive Officer bij NUO THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
David Emerson Jorden's current job(s) include being the CEO, CFO, Secretary & Director at Nuo Therapeutics, Inc. since 2016, and the Chief Executive Officer & Director at Nanospectra Biosciences, Inc. since 2013.
Mr. Jorden's former job(s) include being the Chief Financial Officer & Director at PLx Pharma, Inc., a Director at Opexa Therapeutics, Inc. from 2008 to 2013, a Vice President at Morgan Stanley from 2003 to 2008, a Principal at Fayez Sarofim & Co., and the Chief Financial Officer & Vice President at Genometrix, Inc. from 2000 to 2002.
Additionally, he served as the Chief Financial Officer at PLx Pharma, Inc. from 2015 to 2017.
Mr. Jorden's education history includes an undergraduate degree from The University of Texas at Austin in 1984 and an MBA from Kellogg School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
NUO THERAPEUTICS INC
4.46% | 15-03-2023 | 1 975 358 ( 4.46% ) | 2 M $ | 31-03-2024 |
Actieve functies van David Jorden
| Bedrijven | Functie | Begin |
|---|---|---|
| NUO THERAPEUTICS, INC. | Chief Executive Officer | 08-01-2016 |
Nanospectra Biosciences, Inc.
 Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Chief Executive Officer | 01-06-2013 |
Eerdere bekende functies van David Jorden
| Bedrijven | Functie | Einde |
|---|---|---|
| PLX PHARMA WINDDOWN CORP. | Director of Finance/CFO | 01-07-2017 |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Director of Finance/CFO | 02-04-2013 |
| MORGAN STANLEY | Corporate Officer/Principal | - |
Genometrix, Inc.
 Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Genometrix, Inc. performs commercial physical and biological research. The private company is based in The Woodlands, TX. | Director of Finance/CFO | 01-09-2002 |
Fayez Sarofim & Co.
 Fayez Sarofim & Co. Investment ManagersFinance Fayez Sarofim & Co. (FSC) is a SEC-registered investment advisor headquartered in Houston, Texas. The firm was founded by Fayez Sarofim in 1958 and is a wholly-owned subsidiary of The Sarofim Group, Inc. FSC manages investment portfolios for a wide range of clients which includes pension plans, foundations, endowments and individuals. | Corporate Officer/Principal | - |
Opleiding van David Jorden
| The University of Texas at Austin | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| MORGAN STANLEY | Finance |
| NUO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Fayez Sarofim & Co.
Fayez Sarofim & Co. Investment ManagersFinance Fayez Sarofim & Co. (FSC) is a SEC-registered investment advisor headquartered in Houston, Texas. The firm was founded by Fayez Sarofim in 1958 and is a wholly-owned subsidiary of The Sarofim Group, Inc. FSC manages investment portfolios for a wide range of clients which includes pension plans, foundations, endowments and individuals. | Finance |
Genometrix, Inc.
Genometrix, Inc. Miscellaneous Commercial ServicesCommercial Services Genometrix, Inc. performs commercial physical and biological research. The private company is based in The Woodlands, TX. | Commercial Services |
PLx Pharma, Inc. /Old/
 PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
PLx Pharma, Inc.
 PLx Pharma, Inc. Pharmaceuticals: MajorHealth Technology PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of a technology platform for approved drugs. It offers the PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Dover, DE. | Health Technology |
